MIRM

Mirum Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000

$85.00Close $4.4BMarket cap $64.10 – $128.5752-week range Nov 3, 2026Next report · after the close

Highlights

Cautions

Not in an uptrend 3 of 8 trend conditions
Lagging the market RS 28 · weaker than 72% of stocks over 12 months
Far from its high 34% below its 52-week high
Results soon Nov 3, 2026, in 2 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 5, 2026

Off 12-month high 34%

1wk 5.7% price change

1mo 0.6% price change

12-month return 18% market up 11% · its own up 10%

F-score — — Not assessed

Altman Z 4.92 Low risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 14.0× price / book

Earnings yield 0.5% EBIT / enterprise value

Cheaper than 21% of the market · expensive

Revenue growth 55% year on year

EPS growth — latest quarter

Sales growth 38% latest quarter · -5 pts

ROE 9% return on equity

Free cash margin 11% $54.9M FCF

D/E — long-term debt / equity

Net debt / EBITDA -140.7× net cash

Interest cover —EBIT / interest

Trade setup

ATR% 4.2% $3.60 a day · 2×ATR $77.80

RS 28 / 99 vs the universe

Trend 3 / 8 trend template

Relative volume 1.0× vs 50-day average

Up/down volume 0.97 50 sessions

Implied move — no option chain · report Nov 3, 2026

Trend template · 3 of 8

Price above the 150 and 200-day averages: fails
150-day average above the 200-day: passes
200-day average rising for a month: passes
50-day average above the 150 and 200-day: fails
Price above the 50-day average: fails
At least 30% above the 52-week low: passes
Within 25% of the 52-week high: fails
RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 7.4% over the year, from 48m to 52m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Aug 5, 2026

Last shock Aug 6, 2026-11% in one session3.4× volumeon results-10% since

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $521.3M +55% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$23.4M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $54.9M +488% on FY2024

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Net -4%
Free cash 11%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 51.90m +74.3% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$0	$19.1M	$77.1M	$186.4M	$336.9M	$521.3M
Operating income	-$104.3M	-$173.4M	-$131.2M	-$109.2M	-$87.6M	-$22.1M
Net income	-$103.3M	-$84.0M	-$135.7M	-$163.4M	-$87.9M	-$23.4M
Net margin	—	-439%	-176%	-88%	-26%	-4%
Earnings per share	—	-$2.77	-$3.99	-$4.00	-$1.85	-$0.47
Free cash flow	-$89.3M	-$132.8M	-$120.4M	-$71.1M	$9.3M	$54.9M
Free cash margin	—	-694%	-156%	-38%	3%	11%
Cash	$142.1M	$31.3M	$28.0M	$286.3M	$222.5M	$296.7M
Shareholders' equity	$172.1M	$120.2M	$142.0M	$248.7M	$225.6M	$314.7M
Shares outstanding	29.78m	30.58m	36.96m	46.72m	48.34m	51.90m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 5, 2026	Quarterly ↗	Jun 30, 2026	36d
May 6, 2026	Quarterly ↗	Mar 31, 2026	36d
Feb 25, 2026	Annual ↗	Dec 31, 2025	56d
Nov 4, 2025	Quarterly ↗	Sep 30, 2025	35d
Aug 6, 2025	Quarterly ↗	Jun 30, 2025	37d
May 7, 2025	Quarterly ↗	Mar 31, 2025	37d
Feb 26, 2025	Annual ↗	Dec 31, 2024	57d
Nov 12, 2024	Quarterly ↗	Sep 30, 2024	43d
Aug 7, 2024	Quarterly ↗	Jun 30, 2024	38d
May 8, 2024	Quarterly ↗	Mar 31, 2024	38d
Mar 15, 2024	Annual ↗	Dec 31, 2023	75d
Nov 2, 2023	Quarterly ↗	Sep 30, 2023	33d

Current reports

Filed	Disclosed
Oct 26, 2026	Other events ↗
Oct 13, 2026	Other events ↗
Sep 28, 2026	Other events ↗
Sep 8, 2026	Director or officer change ↗
Aug 5, 2026	Results ↗
Jun 18, 2026	Shareholder vote ↗
May 18, 2026	Material agreement · New obligation · Unregistered share sale · Other events ↗
May 6, 2026	Results ↗
May 4, 2026	Other events ↗
Apr 27, 2026	Other events ↗
Feb 25, 2026	Results ↗
Jan 26, 2026	Acquisition or disposal · Regulation FD · Other events ↗